Delix Therapeutics
- Health & Biotech
- Bedford, MA, US
- Private
- delixtherapeutics.com
Biotechnology company developing neuropsychiatric drug candidates; closed a $100M Series C in November 2026.
$100MEquity raised in 2025–20262025 — · 2026 $100M · 1 equity round
$100MEquity raised, all time1 equity round sourced so far
—Latest valuationnot disclosed
Rounds over time log-scaled amounts
Funding history 1 round · 1 source
Earlier rounds not yet sourced. Delix Therapeutics raised before 9 Nov 2026; only the rounds below are sourced so far, so its all-time equity total understates its history.
- Series CAmount$100MPost-money—✓ Confirmed
- Earlier rounds not yet sourced
Investors 12
- Johnson & Johnson Innovation - JJDC1
- SV Health Investors' Dementia Discovery Fund1
- Adage Capital Management
- Artis Ventures
- Bail Capital
- Dolby Family Ventures
- Hamilton Square Partners Management
- OMX Ventures
- RA Capital Management
- UC Investments
- Vestal Point Capital
- YK Bioventures
Highlighted investors led at least one equity round; the number is equity rounds taken part in.
Related companies shared investors
DistalmotionHealth · $150M in 2025–2026Shared: Johnson & Johnson Innovation - JJDCParabilis MedicinesHealth · $975M in 2025–2026Shared: RA Capital ManagementTEKEVERDefense · $580M in 2025–2026Shared: UC InvestmentsCorxelHealth · $287M in 2025–2026Shared: RA Capital Management, Adage Capital ManagementEstuary BiotherapeuticsHealth · $103M in 2025–2026Shared: RA Capital ManagementPsiQuantumDeep Tech · $1B in 2025–2026Shared: Adage Capital Management
Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. Delix Therapeutics and its logo are trademarks of their owners, used here for identification only.
